Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus

• Published in: Experimental and clinical endocrinology & diabetes Vol. 116; no. 1; p. 65
• Main Authors: Chen, W-W, Li, L, Yang, G-Y, Li, K, Qi, X-Y, Zhu, W, Tang, Y, Liu, H, Boden, G
• Format: Journal Article
• Language: English
• Published: Germany 01-01-2008
• Subjects: Adult; Blood Glucose - analysis; Blood Pressure; Diabetes Mellitus, Type 2 - blood; Fasting; Female; Fibroblast Growth Factors - blood; Glycated Hemoglobin A - analysis; Humans; Insulin - blood; Insulin Resistance; Male; Middle Aged; Regression Analysis; Triglycerides - blood; Waist-Hip Ratio
• ISSN: 0947-7349
• DOI: 10.1055/s-2007-985148

Fibroplast growth factor (FGF-21) is a recently discovered metabolic regulator. Its pathophysiologic role in humans remains unknown. In this study, we have investigated whether or not plasma FGF-21 level was different in patients with type 2 diabetes mellitus (T2DM) and non-diabetic controls. We also assessed associations between plasma FGF-21 body composition and several metabolic parameters. Fasting FGF-21 levels were significantly increased in patients with T2DM compared with controls (1.82+/-0.65 VS. 1.53+/-0.60 microg/L, P<0.05). In T2DM patients, fasting plasma FGF-21 correlate negatively with fasting blood glucose ( R= -0.31, P<0.05). Multiple regression analysis showed that FBG, plasma insulin and HOMA (IS) were independent influencing plasma FGF-21 levels. The present work suggests a potential role for FGF-21 in the pathogenesis of insulin resistance and T2DM.